Tesamorelin

What Tesamorelin is

Tesamorelin is a 44-amino acid synthetic peptide analogue of human growth hormone-releasing hormone (GHRH), developed by Theratechnologies Inc. of Montreal, Canada ^[1]. Its defining structural feature is the attachment of a trans-3-hexenoic acid (hexenoyl) moiety at the N-terminus of the native GHRH sequence, which substantially increases resistance to enzymatic degradation and prolongs biological activity compared with endogenous GHRH ^[2]. Theratechnologies pursued tesamorelin as a targeted strategy to address the problem of central fat accumulation observed in HIV-infected patients receiving antiretroviral therapy, noting that low growth hormone levels were closely associated with this phenomenon ^[3]. The compound received U.S. FDA approval in November 2010, becoming the first and, at the time of approval, only pharmacological treatment specifically indicated for the reduction of excess abdominal fat in HIV-associated lipodystrophy ^[4].

As a member of the GHRH analogue compound class, tesamorelin differs meaningfully from direct growth hormone preparations and from unrelated secretagogues such as ghrelin mimetics. Rather than supplying exogenous growth hormone, it works upstream at the pituitary level, preserving the natural hypothalamic–pituitary feedback loop and producing pulsatile—rather than continuous—growth hormone secretion ^[5]. This preservation of physiological signalling patterns is considered an important design advantage, as it allows IGF-1-mediated negative feedback to remain intact and is thought to reduce the side-effect burden associated with supraphysiological growth hormone exposure ^[2].

What it is being researched for

1. HIV-Associated Lipodystrophy and Visceral Adiposity

The primary and most extensively studied application of tesamorelin is the reduction of visceral adipose tissue (VAT) in people living with HIV (PLWH) who develop lipodystrophy—a syndrome of abnormal fat redistribution often linked to antiretroviral therapy ^[3]. A 2026 systematic review and meta-analysis pooling four randomized controlled trials (909 patients) found that tesamorelin significantly reduced VAT, waist circumference, and trunk fat while also increasing lean body mass ^[6]. Two pivotal Phase III trials over 26 weeks confirmed these reductions, and extension phases lasting to 52 weeks demonstrated that improvements were maintained on continued treatment, though VAT reaccumulated rapidly when treatment was discontinued ^[7]. Modest improvements in total cholesterol and triglycerides have also been reported in VAT-responders ^[8]. The evidence base from these trials provided the foundation for FDA approval and remains the most robustly supported area of tesamorelin research.

2. Non-Alcoholic Fatty Liver Disease (NAFLD) in HIV

Researchers have investigated whether tesamorelin's ability to reduce visceral fat and increase pulsatile growth hormone secretion could extend to hepatic fat reduction in HIV-associated NAFLD, a condition that affects more than one-third of people living with HIV and follows a more aggressive course than in the general population ^[9]. A landmark randomised, double-blind, multicentre trial (NCT02196831) found that tesamorelin produced a 37% relative reduction in hepatic fat fraction compared with placebo at 12 months, and substantially attenuated the high rate of liver fibrosis progression observed in the placebo group ^[10]. A follow-up transcriptomic analysis provided mechanistic evidence that these effects are linked to pulsatile growth hormone action on hepatic lipid metabolism and inflammatory gene expression ^[9]. A separate NIH-funded randomised trial (NCT03375788) in non-HIV obese individuals with NAFLD further explored whether similar hepatic benefits are achievable outside the HIV setting ^[11].

3. Neurocognitive Function and Brain Health in Aging

An unexpected but significant line of research concerns tesamorelin's effects on cognition. A double-blind, randomised, placebo-controlled trial conducted at the University of Washington enrolled 152 adults aged 55–87, including individuals with mild cognitive impairment (MCI) and healthy older adults, and reported that tesamorelin improved executive function and, to a lesser degree, short-term verbal memory ^[12]. Specifically, cognitive function improved in healthy adults and the expected decline in those with MCI was attenuated, findings that a Nature Reviews Endocrinology commentary noted implicate the somatotrophic axis as a potential therapeutic target in the earliest stages of age-related cognitive decline ^[12]. An NIH-funded Phase II trial (NCT02572323) also evaluated tesamorelin for HIV-associated neurocognitive disorders, theorising that visceral adiposity reduction and IGF-1 elevation—a factor shown to promote brain angiogenesis, neurite outgrowth, and synaptogenesis—could benefit cognition in aging HIV-positive individuals ^[13].

4. Metabolic Syndrome and Cardiovascular Risk Markers

Beyond the HIV population, researchers have tested tesamorelin in abdominally obese individuals with relative growth hormone deficiency who have no HIV infection. A 12-month randomised, double-blind, placebo-controlled trial (n=60) found that tesamorelin selectively reduced VAT without significantly affecting subcutaneous adipose tissue and was associated with improvements in triglycerides, C-reactive protein, and carotid intima-media thickness (cIMT)—a surrogate marker of atherosclerosis—without worsening glucose metabolism ^[14]. A subgroup analysis of the Phase III HIV trial datasets further assessed 10-year atherosclerotic cardiovascular disease (ASCVD) risk scores, finding a trend toward reduced CVD risk prediction driven predominantly by reductions in total cholesterol, even among participants already receiving lipid-lowering therapy ^[15]. These findings support ongoing interest in tesamorelin as a research tool for understanding GH-axis contributions to cardiometabolic risk.

5. Type 2 Diabetes and Glucose Metabolism

A concern with growth hormone-axis modulation is potential adverse effects on insulin sensitivity and glycaemic control. A dedicated randomised, placebo-controlled trial assessed tesamorelin's safety and metabolic effects specifically in patients with type 2 diabetes ^[2]. The study, by Clemmons and colleagues (2017), found that tesamorelin did not significantly alter insulin sensitivity or overall diabetes control over the trial period, and total and non-HDL cholesterol showed modest improvements in the treatment group at week 12 ^[2]. This is considered important because direct recombinant growth hormone administration is well-known to induce insulin resistance, and the tesamorelin data suggest that stimulating endogenous pulsatile GH—which preserves IGF-1 negative feedback—may carry a more favourable glycaemic profile ^[2]. Nevertheless, researchers note this area requires further long-term study.

6. Body Composition and Lean Mass

Several studies have examined tesamorelin's effects on lean body mass (LBM) in addition to fat reduction. The 2026 meta-analysis of four RCTs in PLWH reported a significant increase in lean body mass (mean difference +1.42 kg; 95% CI [1.13, 1.71]; p<0.001) alongside visceral fat reduction ^[6]. The same meta-analysis noted that, while hepatic fat and trunk fat were significantly reduced, subcutaneous adipose tissue and overall BMI were not significantly changed ^[6], suggesting tesamorelin acts selectively on metabolically active fat depots rather than producing generalised body fat reduction. Researchers studying response predictors found that participants with baseline metabolic syndrome and elevated triglycerides showed the greatest likelihood of responding with VAT reduction, indicating the potential for personalised research approaches ^[16].

How it is thought to work

Tesamorelin acts as a selective agonist at the growth hormone-releasing hormone receptor (GHRH-R), a G-protein-coupled receptor expressed predominantly on somatotroph cells in the anterior pituitary gland ^[1]. Upon binding, it activates the adenylate cyclase–cyclic AMP (cAMP) intracellular signalling pathway, leading to increased synthesis and secretion of endogenous growth hormone ^[1]. Crucially, because tesamorelin works upstream—stimulating the pituitary rather than delivering growth hormone directly—the resulting GH secretion occurs in a pulsatile pattern that closely mirrors normal physiology, and the IGF-1 negative feedback loop remains intact ^[5]. This is considered a key mechanistic distinction from exogenous recombinant human growth hormone, which can override feedback regulation and produce supraphysiological hormone levels.

Once growth hormone is secreted, it stimulates the liver and peripheral tissues to produce insulin-like growth factor-1 (IGF-1), which is thought to mediate many of tesamorelin's downstream metabolic effects ^[1]. Growth hormone and IGF-1 together promote lipolysis—the breakdown of stored triglycerides—with a preferential effect on metabolically active visceral adipose tissue via activation of hormone-sensitive lipase ^[17]. This regional specificity may explain why tesamorelin reduces visceral fat without producing equivalent reductions in subcutaneous fat ^[7]. At the hepatic level, pulsatile growth hormone signalling modulates lipid metabolism gene expression, decreasing lipogenic gene activity and increasing lipolytic gene expression, providing a molecular basis for observed reductions in liver fat ^[9]. In brain research contexts, IGF-1 elevation is of interest because it promotes processes such as neurogenesis, neurite outgrowth, and synaptogenesis, which may underlie the cognitive associations observed in clinical studies ^[13].

Where the evidence stands

The human evidence base for tesamorelin is unusually robust for a research peptide, anchored by multiple Phase III randomised controlled trials and several subsequent meta-analyses. In the HIV-lipodystrophy setting, a 2026 meta-analysis pooling four RCTs (909 patients) confirmed statistically significant reductions in VAT, waist circumference, trunk fat, hepatic fat, and lean mass increases, all with well-characterised effect sizes ^[6]. A separately published 2025 meta-analysis with systematic literature coverage through July 2025 reached concordant conclusions and additionally noted the absence of serious glucose-related adverse events ^[17]. For NAFLD, a multicentre randomised trial demonstrated a 37% relative reduction in liver fat and attenuation of fibrosis progression at 12 months in HIV-positive participants, representing the first evidence of a pharmacological agent achieving this outcome in HIV-associated NAFLD ^[10]. In the neurocognitive domain, a 20-week placebo-controlled trial in 152 older adults found improvements in executive function tests and an attenuation of expected cognitive decline in MCI participants ^[12]. A small randomised trial in obese, non-HIV participants demonstrated reductions in cardiovascular surrogate markers including cIMT and CRP, alongside triglyceride lowering ^[14].

Despite this breadth, important limitations exist. The majority of the highest-quality evidence is confined to people living with HIV, limiting direct generalisability to the general population; researchers note that evidence in non-HIV populations with obesity or metabolic syndrome is limited and long-term outcomes are not well established ^[8]. The VAT reduction observed in trials is not permanent: discontinuation of tesamorelin results in reaccumulation of visceral fat ^[7]. Cognitive benefits have been observed in one primary trial and have not yet been fully replicated or mechanistically explained in large independent studies. The type 2 diabetes study was of relatively short duration and modest sample size ^[2]. Cardiovascular hard outcomes (myocardial infarction, stroke, mortality) have not been reported in prospective trials; the cardiovascular data remains based on surrogate markers and subgroup analyses ^[15]. Researchers continue to explore the compound's effects in non-HIV metabolic populations, aging cohorts, and other conditions where the GH-IGF-1 axis is disrupted.

Frequently asked questions

What is tesamorelin and how is it different from human growth hormone?

Tesamorelin is a synthetic peptide that mimics the body's own growth hormone-releasing hormone (GHRH), stimulating the pituitary gland to produce growth hormone naturally and in pulses rather than delivering growth hormone directly. This indirect mechanism preserves the normal IGF-1 feedback loop and is associated with a different safety profile compared to exogenous recombinant human growth hormone. It is a GHRH analogue, not growth hormone itself.

Is tesamorelin FDA-approved?

Yes. The U.S. FDA approved tesamorelin (brand name Egrifta) in November 2010, making it the first and only pharmacological treatment specifically indicated for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. Use outside this approved indication is considered off-label and is the subject of ongoing research.

What conditions is tesamorelin being researched for beyond HIV lipodystrophy?

Beyond its approved HIV-lipodystrophy indication, tesamorelin is actively studied for non-alcoholic fatty liver disease (NAFLD), neurocognitive function in aging and mild cognitive impairment, cardiovascular risk markers in metabolic syndrome, and metabolic effects in type 2 diabetes. Evidence in non-HIV populations remains more limited than in the HIV setting.

Does tesamorelin affect blood sugar or insulin sensitivity?

Clinical trials have assessed this carefully because growth hormone can impair insulin sensitivity. A dedicated randomised trial in type 2 diabetes patients found that tesamorelin did not significantly alter insulin sensitivity or overall diabetes control, which researchers attribute to the pulsatile GH secretion pattern preserving normal IGF-1 negative feedback. Long-term glucose effects in diverse populations remain an active area of study.

What happens to visceral fat when tesamorelin is stopped?

Clinical trial extension data consistently show that visceral fat improvements are not permanent: when tesamorelin is discontinued, the visceral adipose tissue that was reduced tends to reaccumulate over subsequent months. This finding has been replicated across multiple trials and is an important consideration for researchers evaluating the compound's longer-term utility.

Can tesamorelin affect liver fat?

Yes, a randomised, double-blind, multicentre trial in HIV-positive individuals with NAFLD found that tesamorelin produced a 37% relative reduction in hepatic fat fraction compared with placebo over 12 months, and also attenuated the rate of liver fibrosis progression seen in the placebo group. A separate NIH-funded trial is investigating similar effects in obese non-HIV individuals with NAFLD.

Has tesamorelin been studied for brain health or memory?

Yes. A 20-week placebo-controlled trial in 152 older adults (ages 55–87) found that tesamorelin improved executive function and attenuated the expected cognitive decline in participants with mild cognitive impairment (MCI). Researchers hypothesise that IGF-1 elevation may support neurobiological processes including neurite outgrowth and synaptogenesis, though this is an emerging area that requires further investigation.

What are the known safety concerns associated with tesamorelin in research?

Across clinical trials, tesamorelin has been generally well-tolerated with no serious glucose perturbation reported in most studies. The most commonly reported adverse events in trial cohorts included headache and injection-site reactions such as erythema. Researchers note that longer-term safety data beyond 52 weeks remain limited, and the compound is not recommended for human self-use outside of medically supervised research or prescription contexts.

Does tesamorelin reduce subcutaneous fat as well as visceral fat?

The evidence consistently shows that tesamorelin acts selectively on visceral adipose tissue (the fat surrounding internal organs) rather than subcutaneous fat (the fat under the skin). Meta-analyses of randomised trials found significant reductions in VAT, trunk fat, and waist circumference, but no statistically significant reductions in subcutaneous adipose tissue or overall BMI, suggesting a regionally specific mechanism of action.

Is tesamorelin the same as sermorelin or CJC-1295?

No. Tesamorelin, sermorelin, and CJC-1295 are all GHRH analogues that stimulate endogenous growth hormone secretion, but they differ structurally, in their pharmacokinetic profiles, and in their evidence bases. Tesamorelin is the only one with FDA approval for a clinical indication, and it has undergone the most extensive Phase III randomised controlled trial evaluation.

Glossary

GHRH (Growth Hormone-Releasing Hormone)

A peptide hormone produced in the hypothalamus that signals the anterior pituitary gland to synthesise and release growth hormone; tesamorelin is a synthetic, stabilised analogue of this molecule.

Somatotroph

A specialised cell type in the anterior pituitary gland that produces and secretes growth hormone in response to GHRH receptor activation.

IGF-1 (Insulin-Like Growth Factor-1)

A hormone produced primarily by the liver in response to growth hormone stimulation that mediates many of growth hormone's metabolic and anabolic effects, including lipolysis and protein synthesis.

Visceral Adipose Tissue (VAT)

The fat depot located within the abdominal cavity surrounding internal organs; elevated VAT is associated with increased metabolic and cardiovascular disease risk.

HIV-Associated Lipodystrophy

A syndrome of abnormal fat redistribution—including visceral fat accumulation and peripheral fat loss—observed in people living with HIV, often linked to antiretroviral therapy.

Pulsatile Secretion

The natural pattern of hormone release in discrete bursts rather than continuously, which is important for maintaining receptor sensitivity and physiological feedback mechanisms.

NAFLD (Non-Alcoholic Fatty Liver Disease)

A condition characterised by excess fat accumulation in the liver not caused by alcohol, ranging from simple steatosis to potentially progressive steatohepatitis and fibrosis.

Carotid Intima-Media Thickness (cIMT)

A non-invasive ultrasound measurement of the thickness of the inner layers of the carotid artery wall, used as a surrogate marker of subclinical atherosclerosis and cardiovascular risk.

References

1. Tesamorelin: Exploring the Research Potential of a Growth Hormone-Releasing Peptide — BioSpace
2. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial — PLOS ONE / PubMed Central (DOI: 10.1371/journal.pone.0179538)
3. Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy — HIV/AIDS – Research and Palliative Care / PubMed (DOI: 10.2147/HIV.S14561)
4. Spotlight on tesamorelin in HIV-associated lipodystrophy — BioDrugs / PubMed (DOI: 10.2165/11208290-000000000-00000)
5. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy — Annals of Pharmacotherapy / PubMed (DOI: 10.1345/aph.1Q629)
6. Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis — PubMed Central
7. Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial — PubMed Central
8. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin — Clinical Infectious Diseases / PubMed
9. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD — JCI Insight / PubMed Central
10. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial — The Lancet HIV (DOI: 10.1016/S2352-3018(19)30338-8)
11. ClinicalTrials.gov – Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease (NCT03375788) — ClinicalTrials.gov
12. Tesamorelin can improve cognitive function (commentary on Baker et al. RCT) — Nature Reviews Endocrinology
13. Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons (NCT02572323) — ClinicalTrials.gov
14. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial — Journal of Clinical Endocrinology & Metabolism / PubMed
15. P-433. Impact of Tesamorelin on Cardiovascular Disease Risk Prediction Scores in Phase 3 Studies Treatment Arms: Subanalysis — Open Forum Infectious Diseases / PubMed Central